IPO registrations (S-1, F-1) · Registrants
Cyteir Therapeutics, Inc.
- SEC CIK
- 1662244 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2021-05-28, last 2021-06-14; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2021-06-21; declared effective 2021-06-17
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- P.O. BOX 80084, Stoneham, MA 02180
- EIN
- 45-5429901
- EDGAR entity type
- operating
- Insiders and CEO pay
- Cyteir Therapeutics, Inc. on the corporate pages
Offering terms
- Proposed price range
- $16.00–$18.00 per share (S-1/A filed 2021-06-14)
- Final price
- $18.00 per share, within the range (424B4 filed 2021-06-21, an initial public offering)
- Shares sold
- 7,400,000
- Gross proceeds
- $133,200,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol CYT
- Lead underwriters
- J.P. Morgan; Morgan Stanley; BofA Securities
- Syndicate
- Wedbush Securities
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: CYTEIR THERAPEUTICS EXACT (EIN (EXACT))
- Federal award recipient: CYTEIR THERAPEUTICS, INC. Fuzzy (name and state)
- Form D issuer: Cyteir Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: Cyteir Therapeutics, Inc. EXACT (CIK (EXACT))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-05-28 | S-1 | S-1 (registration) | Cyteir Therapeutics, Inc. | 0001193125-21-176892 ↗ |
| 2021-06-04 | S-1/A | S-1/A (amendment) | Cyteir Therapeutics, Inc. | 0001193125-21-182985 ↗ |
| 2021-06-14 | S-1/A | S-1/A (amendment) | Cyteir Therapeutics, Inc. | 0001193125-21-189385 ↗ |
| 2021-06-17 | EFFECT | EFFECT (declared effective) | Cyteir Therapeutics, Inc. | 9999999995-21-002394 ↗ |
| 2021-06-21 | 424B4 | 424B4 (final prospectus) | Cyteir Therapeutics, Inc. | 0001193125-21-194049 ↗ |
| 2022-08-16 | EFFECT | EFFECT (declared effective) | Cyteir Therapeutics, Inc. | 9999999995-22-002401 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-06-14 | S-1/A | registration statement | $16.00–$18.00 | 7,400,000 | - | Nasdaq CYT | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2021-06-21 | 424B4 | final prospectus | $18.00 | 7,400,000 | $133,200,000 | Nasdaq CYT | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bracken Racquel | Director | 3 | 2021–2023 | ||
| DF II GP Sarl | TenPercentOwner | 2 | 2021 | ||
| Droia Invest II SCSp | TenPercentOwner | 2 | 2021 | ||
| Gaiero David G | Officer | Chief Financial Officer; Vice President, Finance | 7 | 2021–2024 | |
| Gengos Andrew | Officer | Chief Business Officer | 2 | 2021–2022 | |
| George Jean | Director | 5 | 2021–2024 | ||
| Hong Karen | Director | 1 | 2021 | ||
| IHL SA | TenPercentOwner | 2 | 2021 | ||
| Molineaux Susan | Director | 3 | 2021–2023 | ||
| Naesens Janwillem | Director; TenPercentOwner | 5 | 2021–2022 | ||
| Novo Holdings A/S | TenPercentOwner | 10 | 2021–2023 | ||
| RENSCHLER MARKUS MD | Director,Officer | President and CEO; See Remarks | 7 | 2021–2024 | |
| Romberger Timothy | Director | 4 | 2021–2023 | ||
| Secrist John Paul | Officer | Chief Scientific Officer | 2 | 2021–2022 | |
| Venrock Associates VII, L.P. | TenPercentOwner | 2 | 2021 | ||
| Venrock Management VII, LLC | TenPercentOwner | 2 | 2021 | ||
| Venrock Partners VII, L.P. | TenPercentOwner | 2 | 2021 | ||
| Verelst Luc | TenPercentOwner | 2 | 2021 | ||
| Wepaven BV | TenPercentOwner | 2 | 2021 | ||
| Zakrzewski Joseph S | Director | 12 | 2021–2024 | ||
| Humphrey Jeffrey | Director | 4 | 2021–2023 | ||
| THERO JOHN F | Director | 5 | 2022–2024 | ||
| Sands Stephen H. | Director | 4 | 2022–2024 | ||
| Veness Adam M | Officer | General Counsel | 3 | 2022–2023 | |
| Leonard Braden Michael | TenPercentOwner | 3 | 2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2021-02-17 | Cyteir Therapeutics, Inc. | Biotechnology | Indefinite | $79,999,980 | 22 | 1 |
| 2019-10-15 | Cyteir Therapeutics, Inc. | Biotechnology | Indefinite | $20,200,000 | 6 | 1 |
| 2018-03-28 | Cyteir Therapeutics, Inc. | Biotechnology | $35,000,000 | $5,833,326 | 12 | 2 |
| 2015-12-30 | Cyteir Therapeutics, Inc. | Other Health Care | $5,817,996 | $5,817,996 | 15 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | CYTEIR THERAPEUTICS | MA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Federal award recipient | CYTEIR THERAPEUTICS, INC. | MA | Federal spending (USAspending) | name and state |
| Form D issuer | Cyteir Therapeutics, Inc. | MA | Form D private offerings | CIK (EXACT) |
| Patent assignee | Cyteir Therapeutics, Inc. | MA | Patents (USPTO) | name and state |
| SEC filer | Cyteir Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Cyteir Therapeutics, Inc. | MA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | CYTEIR THERAPEUTICS | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, MA first:
- Korro Bio, Inc. MA
- ERGO SCIENCE CORP MA
- MILLENNIUM PHARMACEUTICALS INC MA
- ESSENTIAL THERAPEUTICS INC MA
- ARQULE INC MA
- ASCENT PEDIATRICS INC MA
- EPIX Pharmaceuticals, Inc. MA
- PRAECIS PHARMACEUTICALS INC MA
- PARATEK PHARMACEUTICALS INC MA
- PREDIX PHARMACEUTICALS HOLDINGS INC MA
In other datasets, the same topic (Health) in MA:
- Nonprofit: ABBIE M GRIFFIN HOSPITAL FUND (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health